Proclaim family of SCS IPG
ABBOTT MEDICAL · Decision date Sep 23, 2026
What did the FDA approve?
FDA database entry P010032/S260 records an approval dated 2026-09-23 for a material change to the encapsulant used in the printed circuit board assembly during manufacture of the Proclaim Spinal Cord Stimulator, Proclaim Dorsal Root Ganglion stimulator, and Infinity Deep Brain Stimulator Implantable Pulse Generator devices. The applicant is Abbott Medical, and the supplement type is Real-Time Process with the stated reason 'Change Design/Components/Specifications/Material.'
This supplement is not a new approval of the whole system. The source statement reports the purpose of the change but does not provide independent proof of safety or clinical effectiveness. Specific information absent from the record includes the previous and new encapsulant materials, the manufacturing site, and any supporting test data.
FDA approval order statement
approval for a material change to the encapsulant used in the printed circuit board assembly (PCBA) during the manufacture of the Proclaim Spinal Cord Stimulator (SCS), Proclaim Dorsal Root Ganglion (DRG) stimulator and Infinity Deep Brain Stimulator (DBS) Implantable Pulse Generator (IPG) devices.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Neurology
- Decision date
- Sep 23, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P010032/S260
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- LGW
- Decision code
- APPR
- Decision date
- Sep 23, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, spinal-cord, totally implanted for pain relief.
- Applicant
- Abbott Medical
- Product code
- LGW
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P010032. Subsequent supplements may change the device or its indications.
FDA decision timeline
P010032 · Original PMA
GENESIS AND EON FAMILY NEUROSTIMULATION (IPG) SYSTEMS
P010032/S260 received
Application receipt date recorded by FDA.
P010032/S261 · Related supplement
Spinal Cord Stimulation (SCS) Implantable Pulse Generator (IPG) Charger
P010032/S251 · Related supplement
Quattrode; Octrode; Penta; Lamitrode; Tripole; TriCentrus Lead Extensions
P010032/S260 · FDA decision
Real-Time Process
P010032/S265 · Related supplement
Eterna Spinal Cord Stimulation (SCS) Implantable Pulse Generator
P010032/S262 · Related supplement
Spinal Cord Stimulation (SCS) External Pulse Generator (EPG)
P010032/S264 · Related supplement
Spinal Cord Stimulation (SCS) Implantable Pulse Generator (IPG) Charger
P010032/S266 · Related supplement
Spinal Cord Stimulation (SCS) Implantable Pulse Generator (IPG)
Timeline entries are records held by MedtechLedger for P010032. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P010032
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA approval | Nov 21, 2001 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Sep 11, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Sep 18, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 27, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 28, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA |
Explore the linked device profile
Other records with product code LGW
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Neuromodulation | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 29, 2026 | FDA | |
Saluda Medical Evoke SCS SystemP190002/S052 | Saluda Medical Pty, Ltd. | PMA supplement | Oct 16, 2026 | FDA |
Saluda Medical Evoke SCS SystemP190002/S051 | Saluda Medical Pty, Ltd. | PMA supplement | Oct 15, 2026 | FDA |
| Medtronic Neuromodulation | PMA supplement | Oct 6, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 6901 Preston Rd., Plano, TX, 75024
Sources and methodology
- Original FDA record: P010032/S260
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records






